
Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

CAC builds biofuel plant for OMV
CAC has been assigned by OMV with overall responsibility for the construction of a biofuel plant in which biogenic input materials are processed...

Servier and MiNA Therapeutics sign €220m deal
Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

EU life science PPPs face less budget in Horizon Europe
The EU’s Public-Private Partnerships (PPPs), which have been under fire by the European Parliament and were renamed into ‘European Partnerships‘, are...

Roche in take-over deal with GenMark Diagnostics
The US$1.8bn cash merger – US$ 24.05 per share – is set to close in Q2/2021. The price represents a premium of approximately 43% to GenMark’s...

EMA: AZD1222 causes serious rare ADEs
However, the EMA has no idea which component of the cheapest COVID-19 vaccine on the market is supposed to cause the splanchnic leg and sinus vein...

LSP leads €21m round into Neurent Medical
Galway-based medical device company Neurent Medical, which is focussed on chronic inflammatory diseases of the sinuses and nasal passages said it...